Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration

Evotec AG today announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture in support of MMV’s Malaria and Pathogen Box initiatives. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-medicines-for-malaria-venture-announce-a-long-term-compound-management-collaboration-5231

Weiterlesen

Evotec receives first milestones in TargetAD collaboration

Evotec AG today announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of three selected targets from the TargetAD database. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-first-milestones-in-targetad-collaboration-5225

Weiterlesen

Evotec to collaborate with Fraunhofer in joint drug discovery programmes

Evotec AG announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-collaborate-with-fraunhofer-in-joint-drug-discovery-programmes-5221

Weiterlesen

Evotec receives milestone payment as part of its discovery alliance with Boehringer Ingelheim

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 1.0 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5217

Weiterlesen

Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy

Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-eternygen-enter-collaboration-to-identify-and-develop-novel-metabolic-disease-therapy-5205

Weiterlesen